September 22nd 2023
For prostate cancer awareness month, Bamidele A. Adesunloye, MD, MS, and Evan Pisick, MD, discussed recent changes and new developments that have been added to the treatment landscape.
September 19th 2023
September 14th 2023
September 8th 2023
Morgans and Choudhury Break Down Prostate Cancer Treatment for Heavily Pretreated Patients
August 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Atish D. Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discussed with participants about selecting next-line therapy for metastatic castration-resistant prostate cancer after use of enzalutamide and docetaxel.
Read More
FDA to Quickly Review sNDA for Enzalutamide in nmCSPC With High-Risk BCR
August 23rd 2023The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.
Read More
FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA+ mCRPC
August 11th 2023Results from the phase 3 MAGNITUDE study have led to a quick FDA decision on the future of a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.
Read More
NCCN Guidelines Add Flotufolastat F 18 Injection for Prostate Cancer
July 27th 2023Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted pet imaging agent in prostate cancer. The agent has now been added to the NCCN guidelines.
Read More
Physicians Discuss Targeted Treatment for Prostate Cancer Subtypes
July 10th 2023In the second article of a 2-part article series, Joshua Lang, MD, and live event participants discuss the role of cabazitaxel for the treatment of patients with prostate cancer who harbor certain mutations or have other factors that make their disease unique.
Read More
FDA Grants Approval to Talazoparib Plus Enzalutamide for HRR-Gene Altered mCRPC
June 20th 2023On the heels of an ASCO presentation of data from the phase 3 TALAPRO-2 trial, the FDA has granted approval to the study combination for the treatment of a metastatic castration-resistant prostate cancer subgroup.
Read More
Physicians Discuss the Addition of Cabazitaxel to Treatment in mCRPC
June 20th 2023In the first of a 2-part article series, Joshua Lang, MD, and live event participants discuss how the addition of cabazitaxel to the treatment of patients with metastatic castration-resistant prostate cancer can improve outcomes despite some challenging adverse events.
Read More
mCRPC: Practical Considerations for Real World Use of Lutetium Lu 177 Vipivotide Tetraxetan
June 19th 2023Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.
Watch
Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC: VISION and TheraP Trials
June 19th 2023Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.
Watch
Oncologists Encounter Challenges to Accessing PSMA-Targeted Therapy in Prostate Cancer
June 15th 2023Though the radioligand therapy lutetium Lu 177 vipivotide tetraxetan was approved in 2022 for PSMA-avid patients, several practical considerations have limited its use among patients with prostate cancer.
Read More
BRCA-Mutated mCRPC Has Worse Outcomes Than Non-BRCA HRR Population
June 4th 2023When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.
Read More
Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status
May 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
Read More